The PAX5 CRE (71 clustered mutations across 55 tumors, 7% of all tumors) maps 3-kb downstream of the PAX5 chronic lymphocytic leukemia (CLL) enhancer [15] (Fig. 2c). The gene discussed is PAX5; the disease is B-cell chronic lymphocytic leukemia.